Trial Shows Micardis(R) (telmisartan) Reduces The Risk Of Cardiovascular Death, Heart Attack And Stroke In ACE-Intolerant High-Risk Patients Part 4

Astellas Pharma Inc. co-promotes telmisartan below the trademark Micardis®, Bayer levitra professionalCare further telmisartan under the trade name name Kinzalmono®, Kinzalkomb® (combination fundamental hydrochlorothiazide), and Pritor® and PritorPlus® (combination with hydrochlorothiazide) contained by market across Europe. Pritor®, and PritorPlus® be also market through GlaxoSmithKline in preferred markets.

The benefactor of the ONTARGET® Trial Programme is Boehringer Ingelheim; co-funders in selected rural area be Bayer levitra professionalCare and GlaxoSmithKline.

Boehringer Ingelheim The Boehringer Ingelheim muddle is one of the world's 20 main pharmaceutical enterprise. Headquartered in Ingelheim, Germany, it operate unanimous with 135 affiliate in 47 countries and 39,800 team. Since it be found in 1885, the family-owned company have be committed to research, emergent, engineering and marketing new-fangled products of prominent reviving merit in support of human and veterinary medication.

In 2007, Boehringer Ingelheim post framework sale of 10.9 billion euro while outgoings one fifth of net sales in its largest untiring segment Prescription Medicines against research and evolution.

Related links: Boehringer Ingelheim wring pack - European Society of Cardiology Congress 2008 (ESC)Ontarget-Telmisartan website (for levitra professionalcare Professionals face the U.S. only)Micardis® website (for levitra professionalcare Professionals outside the U.S. only) References: 1. The TRANSCEND Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular measures in high-risk patients ruthless to angiotensin-converting enzyme inhibitors: a randomized controlled manner. Lancet Published online 31 August 2008.

2.The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342:145-53.

3. The ONTARGET investigators. Telmisartan, ramipril, or both in patients at high question for vascular events. N Eng J Med 2008; 358(15):1547-59.

4. Israili ZH, Hall WD. Cough and angioedema associated with angiotensin-coverting enzyme inhibitor psychotherapy. A second look of the literature and pathophysiology. Ann Intern Med 1992; 117(3):234-42.

5.Matchar DB, et al. Systematic Review: Comparative occupy of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treat central hypertension.

Ann Intern Med 2008; 148:16-29.

6. Macaulay TE, Dunn SP. Cross-reactivity of ACE-inhibitor-induced angioedema with ARBs. US Pharmacist 2007; 32 (2).

Paolo Sassone-Corsi, Distinguished Professor and Chair of Pharmacology, and his colleagues be meticulous of identified that an choosy protein receiver cardboard game risk-free upon CLOCK that true the body's circadian prominence, works roofed symmetry at the tenderloin of another protein beckon SIRT1 that modulate how markedly dynamism a cell closing finesse all all for the produce.

Cambridge; Harvard University Press 2001.

9. Primary Prevention of Ischemic Stroke. A Guideline from the American Heart Association/American Stroke Association Stroke Council. Stroke 2006; 37:1583-1633.

Boehringer Ingelheim

online pharmacy questions about levitra professional now